A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderate Alzheimer's Disease. ETHERAL Study
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2018
At a glance
- Drugs ORY 2001 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ETHERAL
- Sponsors Oryzon
- 25 Jun 2018 According to an Oryzon media release, first patient has been enrolled in the UK, at St Pancras Clinical Research.
- 29 May 2018 According to an Oryzon media release, study receives approval in the UK
- 14 May 2018 According to an Oryzon media release, the French regulatory agency, and the Ethics Committee to start the trial in France just a few days ago. The first 3 patients have now been included in two hospitals from Barcelona. The study will be conducted in in UK once the corresponding approvals from the British regulatory authorities are obtained.